Containing zoledronic acid or its salts
Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale: > Other: > Other > Other: > Other: > Containing zoledronic acid or its salts
Duty Rate (from China)
Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Products classified under HTS 3004.90.92.75
Zometa 4mg Intravenous Injection Vial
Zometa is a sterile lyophilized powder containing 4mg of zoledronic acid for reconstitution and intravenous administration to treat hypercalcemia of malignancy and bone metastases. It falls under HTS 3004.90.92.75 as a mixed or unmixed medicament put up in measured doses for therapeutic use, specifically containing zoledronic acid. This classification applies to its retail-packed form for oncology and palliative care.
Reclast 5mg/100ml IV Infusion Solution Premix
Reclast is a ready-to-use 5mg zoledronic acid solution in 100ml bottle for once-yearly intravenous infusion in osteoporosis and Paget's disease treatment. Classified under HTS 3004.90.92.75 due to its zoledronic acid content in measured dose retail packing for prophylactic bone therapy. It qualifies as a mixed product (with excipients) for therapeutic uses.
Zoledronic Acid 4mg Lyophilized Powder for Injection
Generic zoledronic acid 4mg single-dose vial in lyophilized form for reconstitution with sterile water prior to IV use in multiple myeloma and bone metastases. This product is classified in HTS 3004.90.92.75 as an unmixed medicament (post-lyophilization) containing zoledronic acid salts, put up in measured doses for retail sale to hospitals.
Aclasta 5mg Infusion Bag for Osteoporosis
Aclasta (European brand equivalent to Reclast) contains 5mg zoledronic acid in 100ml ready-to-infuse bag for annual osteoporosis prophylaxis in postmenopausal women. It meets HTS 3004.90.92.75 criteria as a zoledronic acid-containing liquid medicament in measured retail dose for prophylactic uses.
Zoledronate Generic 3mg/15ml Concentrate Vial
Concentrated zoledronic acid salt solution 3mg in 15ml vial requiring dilution for tumor-induced hypercalcemia treatment, supplied in single-dose glass packaging. Classified under HTS 3004.90.92.75 for its specific zoledronic acid salt content in measured therapeutic doses.
Zoledronic Acid 4mg + Mannitol Excipient Vial
Lyophilized blend of 4mg zoledronic acid with mannitol stabilizer in 10ml vial for IV reconstitution in palliative bone cancer care. This mixed product qualifies for HTS 3004.90.92.75 as it contains zoledronic acid salts in measured retail doses per Chapter 30 note 3.
Onco-Zol 5mg Ready-to-Use IV Bag
Onco-Zol brand 5mg zoledronic acid premixed infusion in flexible IV bag for oncology floor use treating skeletal-related events. Falls under HTS 3004.90.92.75 as retail-packed zoledronic-containing therapeutic in measured prophylactic doses.